Skip to main content
Daniel Haller, MD, Oncology, Philadelphia, PA

DanielGHallerMDFACP, FASCO, FRCP

Oncology Philadelphia, PA

Emeritus Professor of Medicine, Perelman School of Medicine

Dr. Haller is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Haller's full profile

Already have an account?

  • Office

    3400 Spruce St
    # 15
    Philadelphia, PA 19104
    Phone+1 215-662-3914

Education & Training

  • Georgetown University Hospital
    Georgetown University HospitalFellowship, Medical Oncology, 1976 - 1978
  • MedStar Health/Georgetown University Hospital
    MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 1973 - 1976
  • University of Pittsburgh School of Medicine
    University of Pittsburgh School of MedicineClass of 1973
  • Syracuse University
    Syracuse UniversityBA, Political Science, Magna Cum Laude, 1965 - 1969

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 1980 - 2022
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Fellow Royal College of Physicians, 2013
  • Fellow American Society of Clinical Oncology, 2012
  • Fellow (FASCO) American Society of Clinical Oncologists, 2011
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013  
    Price TJ, Segelov E, Burge M, Haller D, et al., Expert Rev Anticancer Ther., 8/1/2014
  • Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013  
    Papamichael D, Audisio RA, Glimelius B, de Gramont A, Glynne-Jones R, Haller D,et al., Ann Oncol., 7/11/2014
  • Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trial  
    Chu E, Haller D, Cartwright T, et al., Br J Cancer, 2/18/2014
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • A phase II study of celecoxib (C) with irinotecan (I), 5-fluorouracil (F), and leucovorin (L) in patients (pts) with advanced or metastatic colorectal cancer (CRC).
    R. E. Sanborn, H. Lenz, D. G. Haller, A. B. Benson, T. Dragovich, C. Robles, M. McMahon, H. Li, M. Mori, N. Mattek, C. D. Blanke, Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings, 6/1/2006
  • A phase II trial of combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): Preliminary safety analysis.
    M. Hewitt, W. Sun, D. G. Haller, K. Mykulowycz, C. M. Tuite, M. A. Rosen, M. C. Soulen, M. Caparro, B. J. Giantonio, K. M. Olthoff, Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings, 6/1/2006
  • Extended safety and efficacy data on S-1 plus cisplatin in patients with advanced gastric carcinoma in a multi-center phase II study.
    H. Lenz Md, F. C. Lee, D. G. Haller, D. Singh, A. B. Benson, D. Strumberg, R. H. Yanagihara, J. C. Yao, A. T. Phan, J. A. Ajani, Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings, 6/1/2006
  • Join now to see all

Other

  • Integration of full-dose adjuvant chemotherapy with definitive radiotherapy for primary breast cancer. Four year update. 
    Glick JH, Fowble B, Haller DG, Rosato EF, Mackie JA, Weiler C, Glover DJ, Fox KR, Hurwitz S, Goodman RL, NCI Monographs
    1/1/1988
  • Adjuvant chemotherapy in colon and gastric cancer. 
    Macdonald JS, Haller DG, Kisner DL, Recent Results in Cancer Research, Vol. 80. Springer-Verlag
    1/1/1982

Press Mentions

  • Concurrent CRT Effective for Esophageal Cancer in Older Patients
    Concurrent CRT Effective for Esophageal Cancer in Older PatientsAugust 5th, 2021
  • OncLive® and the Ruesch Center to Host the Second Annual Luminary Awards in GI Cancers
    OncLive® and the Ruesch Center to Host the Second Annual Luminary Awards in GI CancersJuly 9th, 2018
  • OncLive® and the Ruesch Center to Honor the Winners of the Luminary Awards in GI Cancers
    OncLive® and the Ruesch Center to Honor the Winners of the Luminary Awards in GI CancersDecember 4th, 2017
  • Join now to see all

Grant Support

  • Eastern Cooperative Oncology GroupNational Cancer Institute1997–2010
  • Bms 182248-01 (Brs/Doxorubicin Conjugate) Administered Every 21 DaysNational Center For Research Resources1998–1999
  • Cancer Education ProgramNational Cancer Institute1991–1999
  • Pilot Study Of Interferon Alpha-2a, 5 Fluorouracil PLUS Calcium LeucovorinNational Center For Research Resources1996
  • Phase II Study Of Infusional Taxol In Metastatic Colorectal CancerNational Center For Research Resources1996
  • Phase I Study Of 90Y-CYT-356 In Metastatic Prostate CancerNational Center For Research Resources1996
  • Cancer EducationNational Cancer Institute1994

Professional Memberships